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In Response:
We thank Dr. Zhang for his 
thoughtful comments on our arti-
cle, “Phase II Trial of Gefitinib in 
Combination with Bevacizumab as 
First-Line Therapy for Advanced Non–
Small Cell Lung Cancer with Activating 
EGFR Gene Mutations: The Okayama 
Lung Cancer Study Group Trial 1001.” 
He raised some important issues about 
bevacizumab (bev) and gefitinib combi-
nation therapy.
Dr. Zhang referred to recent arti-
cles investigating combination therapies 
containing bev in elderly patients1 and 
questioned its tolerability and benefit. 
Both of the articles he cited focus on bev 
in combination with cytotoxic agents, 
showing less efficacy and more toxicity 
in elderly patients. Although the data on 
bev in combination with cytotoxic agents 
for elderly patients are controversial to 
an extent, it seems to be less beneficial 
and more toxic. However, we should 
consider the combination of bev with 
molecular targeted agents such as erlo-
tinib or gefitinib separately because their 
magnitudes of efficacy and toxicologi-
cal profiles differ from cytotoxic agents. 
There is no evidence of higher toxicity 
in elderly patients treated with bev and 
erlotinib or gefitinib. Furthermore, even 
elderly patients with epidermal growth 
factor receptor (EGFR)-mutated lung 
cancers had greater benefit when treated 
with bev in combination with erlotinib.2 
We agree that elderly patients should 
be followed very carefully during treat-
ment, even when bev is combined with 
a molecular targeted agent such as gefi-
tinib or erlotinib, because of their slower 
metabolism, poorer performance status, 
and increased comorbidities, potentially 
leading to greater toxicity.
Regarding cost-effectiveness, 
we agree that economic evaluation is 
essential when developing a new cancer 
treatment as the cost of pharmacologi-
cal cancer therapy is increasing at an 
incredible pace. As Dr. Zhang men-
tioned, an incremental cost-effective-
ness ratio (ICER) per quality-adjusted 
life-year (QALY) gained is often used 
to evaluate cost efficacy and an ICER 
per QALY of less than a certain value 
(£20,000 in the United Kingdom and 
$50,000 in the United States) is gen-
erally considered as cost effective. 
However, calculating the ICER itself 
has potential problems3: difficulty in 
determining such a threshold based 
on evidence; uncertainty in measuring 
utility values; and a tendency to obtain 
a lower QALY in elderly or sicker 
patients with lower expectation of life. 
We should not only include a cost-effi-
cacy parameter in clinical trials but also 
need to have a broad discussion about 
how it should be evaluated.
Finally, we agree with Dr. 
Zhang’s suggestion that it is neces-
sary to identify predictive biomark-
ers of acquired resistance to bev and 
gefitinib. In addition, we need to know 
which mechanisms cause resistance 
to a combination of bev and gefitinib, 
those of bev resistance (angiogenic 
pathways other than the vascular epi-
dermal growth factor pathway4), those 
of gefitinib resistance (secondary 
EGFR T790M mutation, MET ampli-
fication, etc.5), or other yet undefined 
mechanisms. Given that gefitinib itself 
can inhibit EGFR-mutated lung can-
cers, it is unlikely that just bev-resistant 
mechanisms will induce resistance to a 
combination of bev and gefitinib. If bev 
and gefitinib resistance is caused by the 
same mechanisms as those of gefitinib 
resistance, it might be potentially ben-
eficial to continue bev in subsequent 
therapies because the tumors might not 
be resistant to bev itself.
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To the Editor:
Rare epidermal growth factor 
receptor (EGFR) mutations in non–
small-cell lung cancer have been fre-
quently reported in the last decade. A 
high incidence and large variety have 
been identified in several cohorts.1 
Notably, clinical characteristics and 
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EGFR-tyrosine kinase inhibitor (TKI) 
sensitivity of theses rare mutations differ 
from classic EGFR mutant. As a matter 
of fact, they are similar to EGFR wild-
type patients. Lohinai et al.’s2 results 
are in line with previous report. Rare 
EGFR mutations had a high incidence, 
almost the same as classic and synony-
mous (5%, 6%, and 4%; respectively). 
They were also associated with smok-
ing and poor response to EGFR-TKI as 
opposed to classic mutations. In addi-
tion, of the 49 rare mutations, 20 were 
never described before (not registered 
in the Catalogue of Somatic Mutations 
in Cancer [COSMIC] database).
We must be aware that the diag-
nostic of advanced non–small-cell lung 
cancer is often made by biopsy rather 
than resected specimen, and these rare 
mutations were all noted from samples 
of DNA extracted from formalin-fixed 
paraffin-embedded (FFPE) tissue. 
Artifacts can easily be observed when 
sequencing multiple polymerase chain 
reaction (PCR) amplification products 
of very small amounts of DNA, par-
ticularly if the DNA is isolated from 
paraffin-embedded tissue. Therefore, 
the hypothesis that several of these 
rare mutations might be actually 
PCR-amplification artifacts must be 
discussed.
Akbari et al.3 performed direct 
sequencing of the PCR-amplified cod-
ing region of the uracil-DNA glyco-
sylase gene using DNA isolated from 
FFPE tissue specimens from patients 
with gastric cancer (only one mutation 
in the uracil-DNA glycosylase gene 
in human cancer had been previously 
reported in a sporadic human glioblas-
toma). In nearly 35% of the samples, 
they detected base substitutions, which, 
after further investigation, proved to be 
PCR artifacts. They also demonstrated 
that very low concentration of DNA 
template in PCR mix can give rise to 
false base substitutions. Marchetti et 
al.4 identified 45 rare EGFR mutations 
in 70 samples of lung tumor DNA 
extracted from FFPE tissue, and they 
were all found to be artifacts. This was 
confirmed because they also found the 
same mutations in multiple amplifica-
tions of DNA extracted from FFPE of 
normal tissue (50 patients’ lymph nodes 
without neoplasm). In addition, series 
whose fresh-frozen tissue was used do 
not observed rare EGFR mutations.5
There are some hypotheses for 
the occurrence of artifactual mutations. 
For instance, base damages and large-
scale DNA fragmentation caused by the 
chemical preparation of FFPE samples 
might result in cytosine deamination. 
Thereby the taq DNA polymerase would 
insert an adenosine instead of a guano-
sine resulting in C → T and G → A tran-
sitions (so-called “a-rule”). Moreover, 
degraded PCR products allowed the taq 
DNA polymerase performs a “jump” 
from a damaged template to another to 
continue the extension.6
Some strategies were reported to 
prevent artifactual mutations. Routine 
application of microdissection and use 
of fresh-frozen tissue to enrich tumor-
cell DNA are one option. Also, if small 
amounts of DNA extract from FFPE 
were inevitable, addition of uracil-N- 
glycosylase to the DNA template before 
PCR amplification and the examina-
tion of multiple amplifications are 
imperative.
Because analysis of EGFR gene 
is mandatory for decision regarding 
EGFR-TKI use, the correct interpreta-
tion of EGFR exons 18 to 21 sequenc-
ing and its genetic alterations is crucial 
to select patients whom would benefit 
from treatment. Therefore, these data 
preclude the indiscriminate use of 
EGFR-TKI in patients harboring EGFR 
rare mutations and drive us to a more 
careful molecular analysis to identify 
molecular artifacts.
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In Response:
We thank Domingues et al. for 
their comment on our study and the 
opportunity to further discuss the 
clinical relevance of rare epidermal 
growth factor receptor (EGFR) muta-
tions, especially in an era where there 
is an urgent, unmet need to increase the 
number of lung cancer patients who can 
benefit from targeted therapies.
Their comment on the possibility 
that some of the rare mutations identi-
fied during the routine EGFR testing 
might be artifactual is well taken. While 
the demonstration of EGFR mutation is 
required to prescribe EGFR-TKI treat-
ment for lung adenocarcinoma patients, 
there are no definite requirements for 
the sample preparation, molecular diag-
nostic procedures or the type of EGFR 
mutations that needs to be identified. 
Our study was retrospective using the 
mutational data generated during the 
routine molecular pathological diagnosis 
